Analysts’ Viewpoint
Growth in aging population, rise in prevalence of chronic diseases, and increase in number of invasive medical procedures are driving the global catheter-related bloodstream infections market. Surge in number of surgeries and increase in number of patients requiring catheterization are also expected to fuel market expansion.
Increase in adoption of advanced technologies & products for CRBSI infection prevention and treatment, such as antimicrobial-coated catheters and improved diagnostic methods, is presenting significant opportunities for market players.
Leading players are focusing on the development of advanced, safe, and cost-effective products. Government initiatives to promote patient safety and increase in awareness about CRBSIs among healthcare professionals and patients are likely to augment market progress.
Catheter-related bloodstream infection (CRBSI) can be defined as presence of bacteremia after the usage of intravenous catheter. It is a frequent and severe complication of central venous catheterization, and a common cause of nosocomial bacteremia.
Integral to modern practice, intravascular catheters are used for critically-ill patients for administration of fluids, blood products, medication, nutritional solutions, and for hemodynamic monitoring.
Central venous catheters (CVCs) present a significant risk of device-related infections than any other type of medical devices. CVCs are also major causes of morbidity and mortality. These are also the primary source of bacteremia and septicemia in hospitalized patients.
Request a sample to get extensive insights into the Catheter-related Bloodstream Infections Market
Rise in number of invasive medical procedures performed, such as surgeries and cancer treatments that require the use of catheters, increases the risk of infection. This results in higher demand for products and services related to prevention and treatment of these infections. Usage of catheter for a long duration increases the chances of infection. Thus, rise in number of invasive medical procedures is a key driver of the catheter-related bloodstream infection market.
Surge in prevalence of antibiotic-resistant bacteria is another prominent market catalyst. Rise in antibiotic-resistant infections is leading to an increase in demand for products and services that could help prevent and treat these infections.
Rise in prevalence of bloodstream infections, increase in awareness, surge in adoption of minimally invasive procedures, growth in prevalence of antibiotic-resistant bacteria, and higher demand for more effective and safer products are fueling the catheter-related bloodstream infections market.
Growth in aging population is one of the key drivers of the catheter associated bloodstream infections market. The global population over 60 years is expected to double from 11% to 22% between 2000 and 2050. The number of people aged 60 and above is anticipated to increase from 605 million to 2.1 billion during the period.
Incidence of chronic diseases such as diabetes and heart diseases rises with age. This, in turn, increases the risk of CRBSI infections, resulting in higher demand for products and services related to prevention and treatment of these infections.
Aging population is driving the global catheter-related bloodstream infections industry, as older individuals are more likely to require invasive medical procedures. Elderly people are more likely to develop chronic conditions, such as cancer, heart diseases, and diabetes, which require treatment. Several of these conditions require the use of catheters, which increases the risk of CRBSI infection. Hence, older individuals are more likely to develop CRBSI infection and require treatment. Thus, surge in geriatric population is expected to increase the catheter-related bloodstream infections market size.
Request a custom report on Catheter-related Bloodstream Infections Market
In terms of treatment type, the anti-microbial agents segment accounted for the largest market share of more than 75% in 2021. This trend is expected to continue during the forecast period.
Anti-microbial agents, such as antibiotics, can help treat catheter-related bloodstream infections by killing or inhibiting the growth of bacteria that have colonized the catheter or have entered the bloodstream through the catheter. These agents can be administered orally, intravenously, or topically.
It is important to use the appropriate antibiotic based on the type of bacteria causing the infection. It is equally vital to continue treatment for the recommended duration to ensure the infection is fully cleared.
Based on distribution channel, the hospital pharmacies segment dominated the global catheter-related bloodstream infections market in 2021. Most patients prefer hospital pharmacies owing to the convenience of treatment and availability of medicines offered at hospitals. Furthermore, proper diagnosis and availability of multiple options for treating catheter-related bloodstream infections are leading to an increase in number of patient visits to hospital pharmacies. Thus, the hospital pharmacies segment held around 55.0% share of the global market in 2021.
According to catheter-related bloodstream infections industry analysis, North America held the largest share of the global market in 2021. This trend is expected to continue during the forecast period primarily due to the presence of well-established health care infrastructure and technological advancements in the healthcare sector to treat blood-related infections.
Increase in number of people suffering from catheter-related blood infections in the U.S. and Canada, especially the geriatric population, is driving the market in North America. Furthermore, availability of various treatments for catheter associated bloodstream infections is propelling the market in the region.
The market in Asia Pacific is projected to grow at a rapid pace during the forecast period owing to the rise in prevalence of hospital-acquired infections. According to the World Health Organization's Department of Communicable Disease, the risk of healthcare-associated infection is two to 20 times higher in developing countries than that in developed countries.
The global market is highly consolidated, with the presence of small number of key players. These players hold major share in their respective regions. Demand for catheter-related bloodstream infection products has increased in emerging as well as developed markets due to the rise in prevalence of blood stream infections. Growth strategies and focus on research & development by key players are the factors likely to drive the global market.
Leading companies in the global catheter-related bloodstream infections market are Xellia Pharmaceuticals Ltd., Pfizer, Glenmark Pharmaceuticals Ltd., Fresenius Medical Care, CorMedix, Inc., TauroPhar GmbH, Geistlich Pharma, Citus Pharmaceuticals, AstraZeneca, and Merck & Co., Inc.
Prominent players have been profiled in the global catheter-related bloodstream infections market report based on parameters such as product portfolio, recent developments, financial overview, company overview, strategies, and segments.
|
Attribute |
Detail |
|
Size in 2021 |
US$ 1.3 Bn |
|
Forecast (Value) in 2031 |
More than US$ 2.0 Bn |
|
Compound Annual Growth Rate (CAGR) |
5.1% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global industry was valued at US$ 1.3 Bn in 2021
It is projected to reach more than US$ 2.0 Bn by 2031
The CAGR is expected to be 5.1% from 2022 to 2031
Rise in prevalence of bloodstream infections and increase in global geriatric population
Xellia Pharmaceuticals Ltd., Pfizer, Glenmark Pharmaceuticals Ltd., Fresenius Medical Care, CorMedix Inc., TauroPhar GmbH, Geistlich Pharma, Citus Pharmaceuticals, AstraZeneca, and Merck & Co., Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Catheter-related Bloodstream Infections Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Catheter-related Bloodstream Infections Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
4.5. Porter’s Five Forces Analysis
5. Key Insights
5.1. Disease Prevalence & Incidence Rate Globally With Key Countries
5.2. Key Industry Events
5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2017–2031
6.3.1. Anti-microbial Agents
6.3.2. Antibiotic Lock Therapy
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Source of Infection
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Source of Infection, 2017–2031
7.3.1. Coagulase-negative Staphylococcus
7.3.2. S. aureus
7.3.3. Enteric Gram-negative Bacilli
7.3.4. Yeasts
7.3.5. Enterococci & Streptococci
7.3.6. Pseudomonas
7.3.7. Others
7.4. Market Attractiveness Analysis, by Source of Infection
8. Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Catheter-related Bloodstream Infections Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2017–2031
10.2.1. Anti-microbial Agents
10.2.2. Antibiotic Lock Therapy
10.3. Market Value Forecast, by Source of Infection, 2017–2031
10.3.1. Coagulase-negative Staphylococcus
10.3.2. S. aureus
10.3.3. Enteric Gram-negative Bacilli
10.3.4. Yeasts
10.3.5. Enterococci & Streptococci
10.3.6. Pseudomonas
10.3.7. Others
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Treatment Type
10.6.2. By Source of Infection
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Catheter-related Bloodstream Infections Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2017–2031
11.2.1. Anti-microbial Agents
11.2.2. Antibiotic Lock Therapy
11.3. Market Value Forecast, by Source of Infection, 2017–2031
11.3.1. Coagulase-negative Staphylococcus
11.3.2. S. aureus
11.3.3. Enteric Gram-negative Bacilli
11.3.4. Yeasts
11.3.5. Enterococci & Streptococci
11.3.6. Pseudomonas
11.3.7. Others
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Treatment Type
11.6.2. By Source of Infection
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Catheter-related Bloodstream Infections Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017–2031
12.2.1. Anti-microbial Agents
12.2.2. Antibiotic Lock Therapy
12.3. Market Value Forecast, by Source of Infection, 2017–2031
12.3.1. Coagulase-negative Staphylococcus
12.3.2. S. aureus
12.3.3. Enteric Gram-negative Bacilli
12.3.4. Yeasts
12.3.5. Enterococci & Streptococci
12.3.6. Pseudomonas
12.3.7. Others
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Treatment Type
12.6.2. By Source of Infection
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Catheter-related Bloodstream Infections Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2017–2031
13.2.1. Anti-microbial Agents
13.2.2. Antibiotic Lock Therapy
13.3. Market Value Forecast, by Source of Infection, 2017–2031
13.3.1. Coagulase-negative Staphylococcus
13.3.2. S. aureus
13.3.3. Enteric Gram-negative Bacilli
13.3.4. Yeasts
13.3.5. Enterococci & Streptococci
13.3.6. Pseudomonas
13.3.7. Others
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Treatment Type
13.6.2. By Source of Infection
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Catheter-related Bloodstream Infections Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Type, 2017–2031
14.2.1. Anti-microbial Agents
14.2.2. Antibiotic Lock Therapy
14.3. Market Value Forecast, by Source of Infection, 2017–2031
14.3.1. Coagulase-negative Staphylococcus
14.3.2. S. aureus
14.3.3. Enteric Gram-negative Bacilli
14.3.4. Yeasts
14.3.5. Enterococci & Streptococci
14.3.6. Pseudomonas
14.3.7. Others
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Treatment Type
14.6.2. By Source of Infection
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. AstraZeneca
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Strategic Overview
15.3.2. CorMedix, Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Strategic Overview
15.3.3. Citus Pharmaceuticals
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Strategic Overview
15.3.4. Fresenius Medical Care
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Strategic Overview
15.3.5. Glenmark Pharmaceuticals Ltd.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Strategic Overview
15.3.6. Geistlich Pharma
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Strategic Overview
15.3.7. Merck & Co., Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Strategic Overview
15.3.8. Pfizer
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Strategic Overview
15.3.9. TauroPhar GmbH
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Strategic Overview
15.3.10. Xellia Pharmaceuticals Ltd.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Strategic Overview
List of Tables
Table 01: Global Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 02: Global Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2031
Table 03: Global Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 06: North America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2031
Table 07: North America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 08: North America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 09: Europe Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 10: Europe Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2031
Table 11: Europe Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 12: Europe Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Asia Pacific Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 14: Asia Pacific Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2031
Table 15: Asia Pacific Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Asia Pacific Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Latin America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 18: Latin America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2031
Table 19: Latin America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 20: Latin America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 21: Middle East & Africa Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 22: Middle East & Africa Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2031
Table 23: Middle East & Africa Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 24: Middle East & Africa Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Treatment Type, 2021 and 2031
Figure 03: Global Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 04: Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Source of Infection 2021 and 2031
Figure 05: Global Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Source of Infection, 2022–2031
Figure 06: Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 07: Global Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 08: Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Region, 2021 and 2031
Figure 09: Global Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Region, 2022–2031
Figure 10: North America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, 2017–2031
Figure 11: North America Catheter-related Bloodstream Infections Market Analysis and Forecast, by Treatment Type, 2021 and 2031
Figure 12: North America Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 13: North America Catheter-related Bloodstream Infections Market Analysis and Forecast, by Source of Infection, 2021 and 2031
Figure 14: North America Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Source of Infection, 2022–2031
Figure 15: North America Catheter-related Bloodstream Infections Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 16: North America Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 17: North America Catheter-related Bloodstream Infections Market Analysis and Forecast, by Country, 2021 and 2031
Figure 18: North America Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Country, 2022–2031
Figure 19: Europe Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, 2017–2031
Figure 20: Europe Catheter-related Bloodstream Infections Market Analysis and Forecast, by Treatment Type, 2021 and 2031
Figure 21: Europe Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 22: Europe Catheter-related Bloodstream Infections Market Analysis and Forecast, by Source of Infection, 2021 and 2031
Figure 23: Europe Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Source of Infection, 2022–2031
Figure 24: Europe Catheter-related Bloodstream Infections Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 25: Europe Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 26: Europe Catheter-related Bloodstream Infections Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 27: Europe Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 28: Asia Pacific Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, 2017–2031
Figure 29: Asia Pacific Catheter-related Bloodstream Infections Market Analysis and Forecast, by Treatment Type, 2021 and 2031
Figure 30: Asia Pacific Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 31: Asia Pacific Catheter-related Bloodstream Infections Market Analysis and Forecast, by Source of Infection, 2021 and 2031
Figure 32: Asia Pacific Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Source of Infection, 2022–2031
Figure 33: Asia Pacific Catheter-related Bloodstream Infections Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 34: Asia Pacific Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 35: Asia Pacific Catheter-related Bloodstream Infections Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 36: Asia Pacific Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 37: Latin America Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, 2017–2031
Figure 38: Latin America Catheter-related Bloodstream Infections Market Analysis and Forecast, by Treatment Type, 2021 and 2031
Figure 39: Latin America Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 40: Latin America Catheter-related Bloodstream Infections Market Analysis and Forecast, by Source of Infection, 2021 and 2031
Figure 41: Latin America Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Source of Infection, 2022–2031
Figure 42: Latin America Catheter-related Bloodstream Infections Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 43: Latin America Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 44: Latin America Catheter-related Bloodstream Infections Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 45: Latin America Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 46: Middle East & Africa Catheter-related Bloodstream Infections Market Value (US$ Mn) Forecast, 2017–2031
Figure 47: Middle East & Africa Catheter-related Bloodstream Infections Market Analysis and Forecast, by Treatment Type, 2021 and 2031
Figure 48: Middle East & Africa Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 49: Middle East & Africa Catheter-related Bloodstream Infections Market Analysis and Forecast, by Source of Infection, 2021 and 2031
Figure 50: Middle East & Africa Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Source of Infection, 2022–2031
Figure 51: Middle East & Africa Catheter-related Bloodstream Infections Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
Figure 52: Middle East & Africa Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 53: Middle East & Africa Catheter-related Bloodstream Infections Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
Figure 54: Middle East & Africa Catheter-related Bloodstream Infections Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 55: Global Catheter-related Bloodstream Infections Market Share Analysis/Ranking, by Company, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Catheter-related Bloodstream Infections Market
